Business Context and Reporting Period
This Form 6-K filing by Oncolytics Biotech Inc. covers the month of October 2025, specifically dated October 17, 2025. The registrant is a biotechnology company headquartered in Calgary, Alberta, Canada, with operations primarily located in the United States. The filing discloses two material corporate actions: the entry into an At-the-Market (ATM) Sales Agreement and the initiation of a domestication process to change its jurisdiction of incorporation from Canada to the United States.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, or debt levels for the reporting period. The document focuses on capital structure and corporate governance rather than operational financial results.
- Capital Raise Capacity: The company may offer and sell common shares with an aggregate offering price of up to $50.0 million under the new ATM Sales Agreement.
- Transaction Costs: The company will pay the agent (BTIG, LLC) a commission of 3.0% of the gross proceeds from any share sales.
- Use of Proceeds: Net cash proceeds are intended to fund the clinical development of pelareorep, associated research and development expenses, operating costs, and general corporate purposes.
Material Changes
Two significant material events were announced on October 17, 2025:
- At-the-Market Sales Agreement: Oncolytics entered into an agreement with BTIG, LLC to sell up to $50.0 million of common shares. Sales will be conducted at the registrant's discretion based on market conditions.
- U.S. Domestication: The company filed a Form F-4 to change its jurisdiction of incorporation from the Province of Alberta, Canada, to the State of Nevada, USA. This change is expected to be effective on or shortly after January 1, 2026, at which point the company will cease to be a "foreign private issuer" under SEC rules.
Outlook, Risks, and Management Commentary
Management intends for the domestication to reduce regulatory burdens and operating costs associated with dual jurisdiction compliance, thereby facilitating shareholder value creation and capital raising. The choice of Nevada over Delaware was driven by a desire for a more predictable legal environment with codified fiduciary duties, aiming to avoid the increasingly litigious environment in Delaware.
Risks and Contingencies:
- There is no assurance that the domestication will occur on the expected timeline or at all.
- Shareholders will hold equity in a Nevada corporation with rights and privileges that differ from the current Canadian structure; some differences may be material.
- No shares may be offered or sold to persons or companies in Canada under this specific ATM agreement.
Investor Verification Checklist
- Verify the final terms and effective date of the domestication from Alberta to Nevada, specifically regarding the January 1, 2026 target date.
- Review the full text of the At-the-Market Sales Agreement (Exhibit 1.1) for specific conditions, price limits, or termination clauses.
- Confirm the specific differences in shareholder rights between the current Canadian common shares and the future Nevada common shares.
- Monitor future filings for actual share sales executed under the $50.0 million ATM facility and the resulting cash proceeds.